全文获取类型
收费全文 | 99808篇 |
免费 | 6969篇 |
国内免费 | 322篇 |
专业分类
耳鼻咽喉 | 1274篇 |
儿科学 | 2534篇 |
妇产科学 | 2306篇 |
基础医学 | 12440篇 |
口腔科学 | 2061篇 |
临床医学 | 9744篇 |
内科学 | 21793篇 |
皮肤病学 | 1068篇 |
神经病学 | 8652篇 |
特种医学 | 3358篇 |
外国民族医学 | 3篇 |
外科学 | 16224篇 |
综合类 | 1401篇 |
现状与发展 | 1篇 |
一般理论 | 75篇 |
预防医学 | 7883篇 |
眼科学 | 2649篇 |
药学 | 6341篇 |
中国医学 | 142篇 |
肿瘤学 | 7150篇 |
出版年
2023年 | 401篇 |
2022年 | 692篇 |
2021年 | 1646篇 |
2020年 | 880篇 |
2019年 | 1586篇 |
2018年 | 1904篇 |
2017年 | 1399篇 |
2016年 | 1552篇 |
2015年 | 1834篇 |
2014年 | 2727篇 |
2013年 | 4319篇 |
2012年 | 6187篇 |
2011年 | 6456篇 |
2010年 | 3618篇 |
2009年 | 3347篇 |
2008年 | 6123篇 |
2007年 | 6818篇 |
2006年 | 6512篇 |
2005年 | 6661篇 |
2004年 | 6497篇 |
2003年 | 6117篇 |
2002年 | 6104篇 |
2001年 | 787篇 |
2000年 | 546篇 |
1999年 | 772篇 |
1998年 | 1283篇 |
1997年 | 1137篇 |
1996年 | 963篇 |
1995年 | 967篇 |
1994年 | 845篇 |
1993年 | 744篇 |
1992年 | 563篇 |
1991年 | 513篇 |
1990年 | 449篇 |
1989年 | 462篇 |
1988年 | 435篇 |
1987年 | 450篇 |
1986年 | 444篇 |
1985年 | 498篇 |
1984年 | 706篇 |
1983年 | 754篇 |
1982年 | 977篇 |
1981年 | 916篇 |
1980年 | 866篇 |
1979年 | 447篇 |
1978年 | 529篇 |
1977年 | 579篇 |
1976年 | 490篇 |
1975年 | 428篇 |
1974年 | 339篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Denis Nissim-Sabat William H. Farr Kathleen McCune Melanie Stith 《Community mental health journal》1986,22(2):160-165
This study represents the first of a two-stage project. The first phase of the study examined the funding sources for the 40 Community Services Boards in Virginia. Data provided from the Department of Mental Health and Mental Retardation in Virginia examined fee collections which are comprised of direct client, commercial insurance, Medicaid and Medicare. An analysis of quarterly reports from 1982 to 1984 revealed that Medicaid collections have decreased significantly, while commercial insurance reimbursements have increased significantly. These results, although limited to data from Virginia, point to the need to examine if these shifts are occurring nation-wide, and to determine if the shift toward commercial insurance is impacting upon the delivery of services in Community Mental Health Centers. 相似文献
23.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
24.
25.
Anna Krygowska-Wajs William P. Cheshire Zbigniew K. Wszolek Alicja Hubalewska-Dydejczyk Barbara Jasinska-Myga Matthew J. Farrer Marek Moskala Anna Sowa-Staszczak 《Parkinsonism & related disorders》2009,15(9):692-696
ObjectiveTo assess for the presence of gastric dysmotility in familial and sporadic Parkinson disease (PD).Methods10 subjects with familial Parkinson disease (fPD), 35 subjects with sporadic Parkinson disease (sPD), and 15 controls, all from academic tertiary care movement disorders centers, were studied. fPD was defined as the presence of at least 2 affected individuals within 2–3 consecutive generations in a family. Molecular genetic analysis has not revealed, thus far, any known genomic abnormality in these families. Gastric emptying was assessed by dynamic abdominal scintigraphy over 92 min following ingestion of a solid meal containing 99mTc-labeled colloid of 40 MBq activity. The main outcome measures were gastric emptying half-time and radiotracer activity over the gastric area at 46 and at 92 min.ResultsGastric emptying time was delayed in 60% of subjects with PD. In comparison to mean t1/2 of 38 ± 7 min in controls, mean t1/2 was 58 ± 25 min in fPD (p = 0.02) and 46 ± 25 min in sPD (p = 0.10). Both fPD and sPD groups included subjects with delayed gastric emptying at an early stage of disease.ConclusionsPatients with fPD showed significantly delayed gastric emptying in comparison to normal age-matched individuals. Further studies of gastrointestinal dysfunction in PD, particularly fPD, are warranted. 相似文献
26.
Usher syndrome: clinical findings and gene localization studies 总被引:3,自引:0,他引:3
William J. Kimberling Sandra L. H. Davenport Ira Priluck Valorie White Karen Biscone-Halterman Patrick E. Brookhouser Claes G. Mller Gunnar Lund Timothy J. Grissom Michael D. Weston 《The Laryngoscope》1989,99(1):66-72
The issue of genetic heterogeneity is a critical problem in the localization of the gene(s) for Usher syndrome. Based on the data obtained on families studied to date, the differences between type I and type II Usher syndrome appear quite distinct with regard to auditory and vestibular function. Although the majority of families can be confidently diagnosed as typical type I or type II, clinical investigations revealed four families with findings that did not fit into either of the two more common subtypes. These findings emphasize the critical importance of an in-depth clinical analysis concomitant with the linkage investigation to assure accurate subtyping of Usher syndrome. Based on an analysis of only those families with definite type I or type II Usher syndrome, approximately 17% of the genome can be excluded as a potential site of the gene for type I, and 14% can be excluded as the site for the type II gene. This study will continue until the Usher gene(s) is successfully localized. 相似文献
27.
28.
29.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
30.